| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-06-16 |
| タイトル |
|
|
タイトル |
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Pembrolizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
third-line treatment |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
urothelial cancer |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
MATSUO, TOMOHIRO
MIYATA YASUYOSHI
HARADA, JUNKI
ITOH, ITSUHO
MATSUDA, TSUYOSHI
ASAI, AKIHIRO
KONDO, TSUBASA
KURATA, HIROKI
SAKAI, SUZUNA
ITOH, HIDENORI
MITSUNARI, KENSUKE
IMAMURA, RYOICHI
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background/Aim: Pembrolizumab is widely used as second-line (2L) chemotherapy for unresectable advanced urothelial carcinoma (UC). While its anticancer effects are known, survival data, particularly on metastatic status, remain limited. Studies on pembrolizumab efficacy, including survival analyses in third- or later-line (≥3L) settings, are also scarce. This study analyzes pembrolizumab efficacy in locally advanced or metastatic UC in ≥2L settings to provide insights for optimizing treatment sequencing and patient management. Patients and Methods: This retrospective study evaluated the cytoreductive effects and survival outcomes of pembrolizumab as 2L or ≥3L treatment in 113 UC patients. Objective response rates (ORRs) were calculated for all patients and separately for 2L and ≥3L treatment groups. Results: The ORRs were 23.0%, 21.8%, and 26.9% for the entire cohort, 2L treatment group, and ≥3L treatment group, respectively, with no significant intergroup differences. The median OS of total patients was 12.2 months, with no significant difference between the 2L and 3L treatment groups (p=0.120). The OS was significantly shorter in patients with liver metastasis than in those without (p=0.004), whereas no significant OS differences were found among patients with lymph node, bone, and lung metastases. Patients with lymph node-only or single-site metastasis had significantly longer OS than did those with distant-organ or multiple-site metastases. Conclusion: Pembrolizumab offered similar efficacy as 2L and ≥3L therapy in advanced UC, supporting use beyond second-line settings. In addition, metastasis, specifically distant metastasis and liver involvement, predicted poorer OS of advanced UC patients under pembrolizumab. These findings support more informed patient selection and treatment sequencing in real-world care. |
|
言語 |
en |
| 書誌情報 |
en : Anticancer Research
巻 45,
号 6,
p. 2563-2573,
発行日 2025-05-27
|
| 出版者 |
|
|
出版者 |
International Institute of Anticancer Research |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0250-7005 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.21873/anticanres.17628 |
| 権利 |
|
|
権利情報 |
© 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Anticancer research, 45(6), pp.2563-2573; 2025 |
|
言語 |
en |
AR45_2563.pdf (912 KB)
